Short Interest in Hypermarcas (OTCMKTS:HYPMY) Declines By 99.5%

Hypermarcas (OTCMKTS:HYPMY) was the target of a large decrease in short interest in May. As of May 29th, there was short interest totaling 16 shares, a decrease of 99.5% from the May 14th total of 3,352 shares. Approximately 0.0% of the shares of the company are short sold. Based on an average trading volume of 88,307 shares, the short-interest ratio is presently 0.0 days.

Analysts Set New Price Targets

Separately, Zacks Research raised shares of Hypermarcas to a “hold” rating in a report on Wednesday, April 29th. One research analyst has rated the stock with a Strong Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Buy”.

Hypermarcas Price Performance

HYPMY stock traded up $0.12 during trading hours on Tuesday, hitting $4.08. 7,845 shares of the stock traded hands, compared to its average volume of 34,566. The stock has a 50-day simple moving average of $4.52 and a 200 day simple moving average of $4.48. Hypermarcas has a one year low of $3.71 and a one year high of $5.50. The company has a market cap of $2.87 billion, a P/E ratio of 8.49 and a beta of 0.70. The company has a current ratio of 1.27, a quick ratio of 0.84 and a debt-to-equity ratio of 0.61.

Hypermarcas (OTCMKTS:HYPMY) last announced its earnings results on Wednesday, April 29th. The company reported $0.10 earnings per share for the quarter. Hypermarcas had a return on equity of 14.08% and a net margin of 19.41%.The business had revenue of $383.13 million during the quarter. Equities analysts forecast that Hypermarcas will post 0.53 earnings per share for the current year.

About Hypermarcas

Hypermarcas SA is a Brazil-based consumer health and pharmaceutical company whose shares trade over the counter in the United States under the symbol HYPMY. Founded in the early 2000s and headquartered in Rio de Janeiro, the company operates as a holding group for a broad portfolio of branded products in the healthcare and personal care sectors.

Through its various subsidiaries, Hypermarcas develops, manufactures and markets prescription and over-the-counter medications, alongside personal care, baby care, home care and nutritional supplement products.